Bank of Hawaii Decreases Stock Holdings in AstraZeneca PLC (NASDAQ:AZN)

Bank of Hawaii cut its holdings in AstraZeneca PLC (NASDAQ:AZN) by 12.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,088 shares of the company’s stock after selling 1,335 shares during the quarter. Bank of Hawaii’s holdings in AstraZeneca were worth $708,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of AZN. Stratos Wealth Advisors LLC lifted its position in shares of AstraZeneca by 2.0% in the 3rd quarter. Stratos Wealth Advisors LLC now owns 6,699 shares of the company’s stock worth $522,000 after purchasing an additional 133 shares during the period. Bruce G. Allen Investments LLC lifted its holdings in AstraZeneca by 19.1% in the second quarter. Bruce G. Allen Investments LLC now owns 860 shares of the company’s stock worth $67,000 after buying an additional 138 shares during the period. Carnegie Investment Counsel boosted its position in AstraZeneca by 0.8% during the 2nd quarter. Carnegie Investment Counsel now owns 17,269 shares of the company’s stock valued at $1,347,000 after acquiring an additional 138 shares in the last quarter. Crumly & Associates Inc. grew its holdings in shares of AstraZeneca by 2.2% during the 3rd quarter. Crumly & Associates Inc. now owns 6,644 shares of the company’s stock worth $518,000 after acquiring an additional 143 shares during the period. Finally, CANADA LIFE ASSURANCE Co raised its position in shares of AstraZeneca by 40.6% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock worth $34,000 after acquiring an additional 146 shares in the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

AstraZeneca Stock Up 1.2 %

Shares of AstraZeneca stock opened at $66.40 on Tuesday. The company has a 50-day simple moving average of $73.19 and a two-hundred day simple moving average of $77.72. The stock has a market capitalization of $205.88 billion, a PE ratio of 31.77, a price-to-earnings-growth ratio of 1.20 and a beta of 0.47. AstraZeneca PLC has a 52-week low of $60.47 and a 52-week high of $87.68. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The company had revenue of $13.57 billion during the quarter, compared to analyst estimates of $13.08 billion. During the same period in the previous year, the business earned $0.87 EPS. The firm’s revenue for the quarter was up 18.0% on a year-over-year basis. On average, analysts anticipate that AstraZeneca PLC will post 4.1 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on AZN shares. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. TD Cowen increased their price target on shares of AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Finally, Erste Group Bank raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, AstraZeneca currently has an average rating of “Moderate Buy” and a consensus target price of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.